

Abstract

In our study ,there was no difference between the matched treated and matched untreated groups in days on vasopressors ,days on mechanical ventilation ,length of icu stay ,and length of hospital stay in days ,these findings are not surprising and are similar to those found in PROWESS AND ADRESS STUDY .

Our study is limited in that it is a prospective and retrospective analysis and that the number of patients is relatively small.

Finally ... Eli Lilly and company (LLY) announced withdrawal of its xigris (Drotrecogin- α – activated) product in all markets on Oct. 25, 2011 following results of the PROWESS-SHOCK study (116).

Key Words:

evaluation of recombinant activated protein c therapy on the outcome of patients with severe sepsis and septic shock.